NightHawk Biosciences Provides Q3 2023 Business Update
November 20, 2023 16:05 ET
|
NightHawk Biosciences
DURHAM, N.C., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company specializing in the end-to-end development, manufacturing,...
NightHawk Biosciences Provides Q2 2023 Business Update
August 14, 2023 16:05 ET
|
NightHawk Biosciences
DURHAM, N.C., Aug. 14, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company specializing in the end-to-end development, manufacturing,...
NightHawk Biosciences Provides Q1 2023 Business Update
May 15, 2023 16:05 ET
|
NightHawk Biosciences
DURHAM, N.C., May 15, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company specializing in the end-to-end development, manufacturing,...
NightHawk Biosciences Provides 2022 Year End Business Update
March 31, 2023 16:05 ET
|
NightHawk Biosciences
DURHAM, N.C., March 31, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate...
NightHawk Biosciences Provides Third Quarter 2022 Business Update
November 14, 2022 16:01 ET
|
NightHawk Biosciences
DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate...
Nighthawk Biosciences’ Scorpion Subsidiary Announces Grand Opening of its San Antonio Facility
October 21, 2022 08:00 ET
|
NightHawk Biosciences
DURHAM, N.C., Oct. 21, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate...
NightHawk Biosciences Announces Buildout of Advanced Biosafety Level 2 (BSL-2) Laboratory
August 23, 2022 07:30 ET
|
NightHawk Biosciences
DURHAM, N.C., Aug. 23, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate...
NightHawk Biosciences Provides Second Quarter 2022 Business Update
August 10, 2022 16:05 ET
|
NightHawk Biosciences
DURHAM, N.C., Aug. 10, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate...
NightHawk Biosciences Appoints Stephan Kutzer, Ph.D. as Interim Chief Executive Officer of Scorpion Biological Services
June 13, 2022 08:00 ET
|
NightHawk Biosciences
DURHAM, N.C., June 13, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate...
NightHawk Biosciences Provides First Quarter 2022 Business Update
May 16, 2022 16:44 ET
|
NightHawk Biosciences
DURHAM, N.C., May 16, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate...